Research Interests
The Faculty maintains an extensive database of individual research profiles. Structured around a fixed list of 70 broad research terms, profiles are maintained by staff themselves and are regularly updated. Be sure to make regular visits...
 | | |
|---|
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
| Dr Margaret Faedo
Prince of Wales Clinical SchoolStatement of Interests:
One of the biggest challenges facing health care systems today is providing patients with access to new and emerging drug treatments, and at the same time ensuring the sustainability of funding. Local health care delivery systems, such as area health services, hospitals and private health insurers are under considerable pressure to fund medicines rejected, restricted or pending approval by the Pharmaceutical Benefits Advisory Committee. There is a need to develop freely available economic models that can adapt easily to local circumstances. This requires new policies and health care practices developed on the basis of sound clinical and economic evidence. Our NHMRC funded program aims to build and disseminate readily accessible evidence about the cost effectiveness of cancer medicines in clinical practice. These models will be available on the Cancer Institute NSW Standard Treatment (CI-SCaT) program, an online resource of more than 500 peer-reviewed cancer treatment guidelines. This is a world first program which will have implications beyond cancer management, addressing one of the most enduring problems in health care: the translation of economic evidence into policy and clinical practice.
More...
| |
| Dr Sallie-Anne Pearson
Prince of Wales Clinical SchoolStatement of Interests:
Sallie is a health service researcher specialising in clinician behaviour change, pharmacoepidemiology and pharmaceutical policy evaluation. She has conducted this research in Australia, the United States and the developing world. Sallie completed her doctoral training in 1998 at the University of Newcastle, Australia and was the inaugural Postdoctoral Fellow in Pharmaceutical Policy at Harvard Medical School from 2000-2001. She returned to Australia in 2002 where she worked as a consultant to the WHO Collaborating Centre in Pharmaceutical Policy Boston and Medicare Australia for two years. She returned to academia in 2004 and in March 2006 joined the Integrated Cancer Research Group as the Pharmacoepidemiology and Pharmaceutical Policy Team Leader. She is currently a Cancer Institute NSW Health Services Research Fellow (2006-2009). Sallie's current research interests focus on three core areas: 1. Using secondary data sources to investigate the use and impact of medicines in real world clinical prcatice 2. Clinician behaviour change, specifically the use and uptake of electronic decision support to guide prescribing practice 3. Investigating the direct and indirect costs of cancer care from the perspective of health care payers and patients
More...
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |